Executives On The Move: Two CEOs, Three CCOs And One COO Among This Week’s Changes
Recent moves in the industry include C-suite changes at Ribometrix and Emyria, plus Arvinas acquires chief commercial officer from Lexicon Pharmaceuticals.
More from Executives On The Move
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
Recent moves in the industry include C-suite changes at Ironwood Pharmaceuticals and Procaps Group, plus Viracta Therapeutics acquires chief executive officer from Molecular Templates.
Recent moves in the industry include changes at the top at Shanghai Bao Pharmaceutical and Alumis, plus Nurix Therapeutics acquires chief commercial officer from Arvinas.
Recent moves in the industry include C-suite changes at Ribometrix and Emyria, plus Arvinas acquires chief commercial officer from Lexicon Pharmaceuticals.
More from Scrip
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.